Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer Abstract #1817

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Aim(s): To assess the biodistribution and present reasonable estimates of normal organ doses to liver, spleen and kidneys using 177 Lu-DOTATATE and Capecitabine.
Materials and methods: Fifteen patients (mean age 51.4y) of metastatic gastric-intestinal NETs diagnosed with 68Ga-DOTANOC PET-CT,histopathology and biochemical markers were were prescribed oral tablet capecitabine in dose of 500mg/m2 twice daily for 14 days, commencing 9 days prior to PRRT. 6.66 to 7.4 GBq (180-200 mCi) of 177Lu-DOTATATE was infused to each patient with co-infusion of amino acid solution for renal protection. Each patient underwent whole-body scans at 2, 24 and 96 hours post therapy. The organs included in dosimetry were kidney, liver, spleen and tumor sites. All calculations were done using HERMES software
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: DNB, FEBNM Sugandha Dureja
Keywords: PRRT, radiosensitizer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Sugandha Dureja
Authors: Dureja S, Sen I, Pant V, Thak P
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...
#1506 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT
#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study
Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dainik Patel
#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT